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Abstract
In response to repetitive bouts of aerobic exercise, type I diabetes mellitus (T1DM)
female rats demonstrate greater post-exercise blood glucose (BG) recovery during proestrus
than T1DM males. Fuel selection differences may explain sex-related differences in the
blunted counterregulatory responses to subsequent exercise and estrogen (E2) has shown to
mediate fuel metabolism. Evidence of E2’s activation of AMP-kinase (AMPK) may mediate
the metabolic actions of E2. This study aimed to examine sex-related differences in lipid and
glucose metabolism in response to a 4-day aerobic exercise protocol in skeletal muscle and
liver tissue of male and female T1DM-induced (n = 5) and non-T1DM (n = 5) rats. Western
blot analysis and phenol sulphuric acid and β-oxidation activity assays were used to assess
AMPK and gluconeogenic enzyme protein expression, muscle glycogen content, and lipid
oxidation. T1DM and non-T1DM females demonstrated significantly greater β-oxidation
activity in muscle compared to males but this fuel shift towards lipids was not associated
with higher AMPK activity. No muscle glycogen content differences between the sexes were
found. T1DM and non-T1DM females demonstrated higher hepatic G6Pase expression than
males. Therefore, T1DM females may be less susceptible to repeated exercise-induced
hypoglycemia through E2-mediated shift towards lipid oxidation during the proestrus phase.

Keywords
Type I diabetes, exercise, estrogen, fuel selection, lipid metabolism, sex-related differences,
AMPK
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Summary for Lay Audience
Type I diabetes mellitus (T1DM) is a chronic illness that results in disrupted blood
sugar concentrations due to the lack of insulin a hormone which typically helps maintain
blood sugar concentrations. A combination of insulin therapy, diet, and exercise can assist
the management of T1DM. However, participating in consecutive exercise or exercise
training may present a challenge for individuals with T1DM because it can lead to low blood
sugar concentrations, or hypoglycemia onset. The typical physiological responses the body
produces to maintain blood sugar concentrations are less effective in response to successive
aerobic exercise. Interestingly, T1DM females are less affected by these blunted responses to
successive bouts of exercise and normalize blood glucose during and following exercise
more efficiently than T1DM males. During aerobic exercise of moderate intensity, the body
uses a combination of sugars or fats for fuel; however, it has been suggested females use
more fats which in turn conserves other energy sources such as sugars for more efficient
post-exercise recovery. The sex hormone estrogen has been noted to explain this sex-related
difference in fuel selection during exercise. Our laboratory recently demonstrated in response
to repetitive bouts of aerobic exercise during elevated concentrations of estrogen blood
glucose concentrations in T1DM females post-exercise normalised more quickly than T1DM
males. Estrogen has shown to activate a major energy sensor AMP-kinase (AMPK), a known
initiator of fat metabolism, and through this enzyme may create a shift towards using fats as
fuel during exercise. Additionally, estrogen has shown to decrease gluconeogenesis through
expression of key enzymes PEPCK and G6Pase. If this pathway is decreased it may indicate
a shift toward fat utilization, however it is unclear how this may influence T1DM as
gluconeogenesis is the primary supply of glucose (sugars) during exercise. This thesis
investigates sex-related differences in activation of key metabolic regulatory enzymes
iii

involved in fat and glucose metabolism in liver and muscle tissue of male and female T1DM
rats following repetitive exercise. We aimed to investigate if differences in fuel selection
between sexes and diseased states were attributed to the presence of estrogen. Skeletal
muscle and liver tissues were taken on the fourth day of a repetitive exercise protocol which
coincided with the phase of high estrogen concentrations (proestrus). The primary findings of
this study were that T1DM female rats indeed demonstrated higher β-oxidation activity than
T1DM males suggesting increased use of fats as fuel. As tissues were harvested on day 4
during the proestrus phase it can be suggested this shift towards fats may be mediated by the
higher concentrations of estrogen. We did not find that the heightened activation of fat
metabolism led to the conservation of glycogen stores in muscle and liver tissues. In addition,
higher β-oxidation activity was not associated with greater AMPK activation in T1DM
females. A greater expression of gluconeogenic enzyme G6Pase in T1DM and non-T1DM
females suggests that exercise during higher estrogen did not negatively impact T1DM fuel
metabolism, rather an increase in fat availability likely alleviated the challenge to balance
blood glucose concentrations. In conclusion, in response to successive aerobic exercise
during proestrus T1DM females may be at less risk for hypoglycemia development due to a
shift towards fats as fuel, however this was not due to an increase in AMPK, nor did it spare
muscle glycogen stores.
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Chapter 1
1.1

Overview of Type 1 Diabetes Mellitus

Diabetes is an umbrella term used to describe two prevalent metabolic disorders
relating to blood glucose (BG) homeostasis. Both Type I diabetes mellitus (T1DM) and
Type II diabetes mellitus (T2DM) lead to impaired glycemic control and are
characterized by chronic high BG concentrations (CONCENTRATION) (hyperglycemia)
resultant of deficient insulin secretion, action, or a combination thereof1. The more
prevalent of the two diseases, T2DM accounts for approximately 90% of diagnoses in
Canada and results from a combination of genetic, lifestyle, and environmental factors2.
Conversely, T1DM constitutes the remaining 10% of diabetes diagnoses in Canada and is
the result of an autoimmune reaction3. The etiology of T1DM is complex and although
the cause is commonly linked to family history, evidence demonstrates a less than 50%
genetic concordance of T1DM in monozygotic twins suggesting other influences play a
role such as environmental factors4. Although currently most diabetes cases are
predominantly T2DM, the prevalence of T1DM is expected to increase by 5-10%
between 2020 and 2030 in Canada as result of environmental factors which influence the
pathogenesis such as vitamin D deficiency and viral infections (e.g., enterovirus) 3, 4.
Similarly, projections in the US suggest that the incidence of T1DM in individuals
younger than 20 years of age will increase 23% by 20504. With these significant surges in
diagnosed T1DM, it is predicted it will directly cost the Canadian health care system 4.9
billion dollars to manage diabetes by 2030, presenting a significant public health and
economic burden3. Additionally, in conjunction with the COVID-19 pandemic, public
health stress is likely to rise as new studies strongly suggest pre-existing diabetes is
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proposed to be one of the highest risk factors for developing COVID-195. Evidence also
suggests COVID-19 can potentially induce new on-set T1DM and promote the
generation of autoantibodies against pancreatic β -cells. COVID-19 can also trigger
severe diabetic ketoacidosis, which has a 4 to 10% mortality rate5, 6. With predictions that
COVID-19 will become an endemic and the increasing prevalence of diabetes, now more
than ever research efforts need to focus on preventative and interventive tools for the
management of T1DM6, 7.
The pathophysiology of diabetes is rather complex and distinct between the two
major classifications of the disease. In 1984, George Eisenbarth developed a theoretical
model for the pathogenesis of T1DM8, 9. It highlights the progression of the disease in a
single line trajectory starting with predisposed genetic risk, followed by an environmental
trigger that disrupts islet-specific functioning which ultimately leads to pancreatic B-cell
loss and disrupted BG homeostasis9, 10. Although Eisenbarth’s model is still used today,
the complexities of the pathogenesis of T1DM continue to be elucidated which has led to
considerable alterations to the model in order to consider the heterogeneities per stage of
T1DM progression10.
In diabetes mellitus, the innate physiological mechanisms which maintain a narrow
range of BG concentrations are disrupted2, 4. Specifically, due to dysfunctional pancreatic
β-cell action and insulin resistance, individuals with T2DM have impaired insulin
secretion and action1, 11. As a result, despite circulating insulin, glucose homeostasis is
dysregulated, and the body is unable to efficiently use glucose from the bloodstream for
energy processes resulting in hyperglycemia12. Conversely, in T1DM T-cell mediated
destruction of pancreatic β-cell leads to complete β-cell loss and ultimately insulin

3

deficiency and hyperglycemia1, 13, 14. Accompanying pancreatic β-cell destruction,
pancreatic α-cells are also dysregulated in T1DM resulting in elevated glucagon
concentrations14, 15 . In non-diabetic physiological conditions, in response to low BG
concentrations (hypoglycemia) pancreatic α-cells secrete the hormone glucagon to raise
BG concentrations13. Typically, in response to hyperglycemia glucagon is suppressed,
however in T1DM glucagon continues to increase BG concentrations further
exacerbating metabolic disruption due to insufficient insulin1, 13. Diabetic ketoacidosis is
an example of metabolic disruption that can present as a result of continued glucagon
secretion paired with insulin deficiency16. If left untreated, T1DM leads to uncontrolled
lipolysis and elevated concentrations of free fatty acids (FFAs) in the blood stream due to
insufficient insulin to synthesize and store triglycerides in adipose tissue1. FFAs are
metabolized into ketone bodies in the liver and an increased availability of FFAs and
ketone bodies disrupts glucose metabolism by reducing the utilization of glucose.
Excessive production of ketone bodies can increase the acidity of the individuals blood
which may be fatal, especially in children17. Nevertheless, since the discovery of insulin,
T1DM has transformed from a fatal to treatable disease18. Survival and overall health of
the patient with T1DM has significantly improved over the decades, however the
management of T1DM remains unoptimized and is associated with life-threatening
complications19, 20. In part, this is due to the complexity of its etiology and the difficulty
in timely diagnosis10.
Historically, T1DM was considered a disorder in children and adolescents, however
more recently this opinion has changed as it is evident that nearly 50% of T1DM
diagnoses are in adulthood10. This is also supported by the fact that 50% of T1DM
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diagnoses are initially misdiagnosed as T2DM4. Now, clinicians deter from age at onset
as a primary symptom to diagnose T1DM and various methods are used for proper
diagnosis. Typically, the general diagnosis of diabetes includes a “fasting BG higher than
7 mmol/L, a random BG concentration of 11.1 mmol/L or higher with symptoms of
hyperglycemia, or an abnormal 2-hour oral glucose-tolerance test (OGTT)”10, 21. In 2009,
a glycated haemoglobin (HbA1c) concentration over 6.5% was introduced in the diagnosis
guidelines8, 10. Haemoglobin is contained in red blood cells which survive up to three
months, therefore this measurement represents chronic glycemic control over several
months22, 23. The use of HbA1c as a biomarker for T1DM is promising as a 20% increase
in HbA1c has shown to be associated with an 84% increased risk for T1DM within three
years4. More recently, a new staging model was introduced to account for the preclinical
stages of T1DM including the measurement of autoantibodies specifically against β-cell
proteins4, 24. Stage one includes the classification of β-cell autoimmunity which is defined
as the detection of more than one islet autoantibody (AAbs), leading to stage two where
glucose intolerance is presented, and finally stage three is the clinical manifestations of
the disease25. There appears a clear relationship between increasing detectable AAbs and
the incidence of symptomatic diabetes as the Environmental Determinants of Diabetes in
the Young study demonstrated that 5-year incidence of symptomatic T1DM was 47%
higher in children with three AAbs26. Additionally, low C-peptide concentration, an
indicator of severe endogenous insulin deficiency, is used as an initial and on-going
assessment of diabetes10, 27. The Diabetes Control and Complications Trial (DCCT) found
an inverse relationship between C-peptide concentration and short- and long-term
complications related to diabetes28. Currently, the best predictor of T1DM within a year
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before diagnosis is a combination of islet AAbs count and abnormal OGTT29. Thus, the
timely diagnosis of T1DM is significant such that the condition can immediately be
managed through insulin therapy and lifestyle intervention10.
Following the advancement of insulin therapy, in the 1990’s the DCCT was
conducted to examine the benefits of intensive insulin therapy (IIT) versus conventional
therapy (CT)28. A more traditional and generally interventive approach, CT consists of a
one to two daily insulin injections per day to prevent hyperglycemia while not inducing
hypoglycemia28, 30, 31. Conversely, IIT is more extensive and requires multiple, smaller
doses throughout the day which are adjusted based on continual measures of BG
concentrations through self-administered BG tests30. A more preventative approach
mirroring physiological insulin secretion and action, IIT attempts to achieve a more
consistent and normalized BG concentration throughout the day and a target HbA1c of
less than 7%30. Overall, the findings of the DCCT concluded that individuals using IIT
had tighter glycemic control and lower HbA1c28. IIT users had a substantial reduction in
the occurrence of micro- and macrovascular complications such as decreased risk and
progression of retinopathy, neuropathy, and nephropathy28, 30. However, although IIT was
more beneficial for alleviating some disease-associated risks, there was a threefold
increase in the risk of hypoglycemia when compared to CT28, 32–34. Clinically,
hypoglycemia is defined as a BG below 3.0 mmol/L, however symptoms of
hypoglycemia such as loss of consciousness and seizures manifest at concentrations of
3.9 mmol/L35, 36. Hypoglycemic events pose life-threatening complications with adverse
effects on cognitive function and are associated with 4-10% of T1DM-related deaths10, 37.
The strongest predictor of hypoglycemia is a precedent bout of severe hypoglycemia,
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therefore the use of IIT, although considerably beneficial for day-to-day living, should
not be exclusively used to treat and manage T1DM34, 36.

1.2
Benefits, Risks, and Counterregulatory Responses
to Exercise in T1DM
Exercise for the management of T1DM is associated with many positive benefits
including enhanced insulin sensitivity, lower blood pressure, reduced insulin dosage
requirements, and increased overall well-being36, 38, 39. Regular participation in physical
exercise is recommended to minimize the complications associated with T1DM;
improving cardiovascular disease risk marker, blood lipid profiles, and overall bone
health, as well as lowering the risk of diabetic neuropathy and nephropathy36, 39. In
addition, there is evidence in children with T1DM exercise training can reduce HbA1c
concentrations, however this effect is not conclusive in adults40, 41. Yet, 63% of adults
with T1DM do not meet current physical activity guidelines nor do they achieve a healthy
body weight42. Inactivity among this patient population leads to lower skeletal muscle
health and insulin resistance development, impaired glucose and lipid disposal, and
reduced basal metabolic rate39, 42, 43. Loss of bone mineral density and osteoporosis are
also common in inactive T1DM individuals, even in the presence of well-controlled BG
concentrations42. Evidently, exercise for the management of T1DM is beneficial and
should be incorporated into individuals’ daily lifestyle. However, unlike non-diabetic
individuals who can seemingly choose any mode of exercise to practice, recommending
the safest frequency, intensity, duration, and type of exercise for T1DM is challenging
due to altered neuroendocrine and hormonal (counterregulatory) responses to exercise36,
39, 42

.
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Current exercise guidelines for individuals with T1DM recommend 150 minutes of
moderate-intensity or 90 minutes of vigorous-intensity exercise per week with no more
than two consecutive sedentary days40, 44. Research efforts on the benefits of exercise for
T1DM have predominantly focused on acute and chronic aerobic training38. Evidence
strongly suggests aerobic exercise reduces many disease-associated complications and
significantly improves glycemic control45–47. Aerobic exercise has also shown to decrease
insulin dosage requirements, improve lipid concentrations, and cardiovascular fitness48–
50

. A meta-analysis on exercise and T1DM concluded that aerobic exercise training for

longer than three months can decrease HbA1c concentrations particularly in individuals
with an initial HbA1c concentration greater than 8%51. Aerobic exercise has also shown to
improve skeletal muscle components such as muscle capillarization and oxidative
capacity, potentially providing significant metabolic benefits42, 52. A 10-week moderateintensity aerobic exercise intervention demonstrated enhanced insulin sensitivity while
another study demonstrated a decrease in insulin dosage after aerobic exercise training50,
53

. Despite increasing research efforts for the development of exercise strategies for

T1DM, as aforementioned, most individuals with T1DM remain inactive and this is
largely due to the fear of exercise-induced hypoglycemia35. Understandably, after a 45minute exercise session the risk of hypoglycemia during and post-exercise increases by
30-45%, lasting up to 31 hours as a result of exercise-induced increase in insulin
sensitivity and increased glucose uptake (i.e., muscle glycogen repletion) 35, 42 .
Exercise-induced hypoglycemia is a severe risk for individuals with T1DM, however
it is not a phenomenon exclusive to T1DM. Depending on the intensity, duration, and
pre-exercise meal, under normal physiological conditions hypoglycemia may occur but
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rarely ever presents severe risk due to the many counterregulatory mechanisms which
prevent and correct hypoglycemia54, 55. Typically, during moderate-intensity exercise,
individuals without T1DM exhibit a reduction in insulin secretion that is paired with an
increase in glucagon to ensure the rate of glucose utilization by the exercising muscle is
equally matched to glucose provision56. In response to fluctuating BG concentrations,
glucagon stimulates liver glucose release via glycogenolysis and gluconeogenesis (GNG)
and if a reduction in BG persists additional hormones and catecholamines such as
epinephrine, norepinephrine, cortisol, and growth hormone are released in a sequential
pattern57, 58. These hormones also take part in stimulating hepatic glucose production and
induce fatty acid release from adipose tissue. Overall, to ensure sufficient energy is
provided to exercising muscles, these counterregulatory responses initiate metabolic
signaling pathways which produce energy predominantly from fatty acids and glucose59,
60

. The result is relatively stable BG concentrations that can be sustained for several hours

without the need for food intake42.
Counterregulatory responses to exercise in individuals with T1DM are reduced
leading to a mismatch between glucose utilization to glucose provision. In T1DM, as a
result of β-cell loss and function, exogenous insulin is required to maintain BG
homeostasis42. Unlike endogenous insulin which has a half-life of approximately 5
minutes, exogenous insulin has a significantly higher half-life lasting up to hours42, 61.
Therefore, the concentrations of insulin prior exercise are dependent on the timing and
quantity of insulin therapy taken by the patient. Due to the timing and peak action of
exogenous insulin, it is likely individuals with T1DM have higher concentrations of
insulin prior exercise42, 61. Elevated insulin may suppress the glucagon response to
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exercise and limit glucose production by the liver namely GNG while stimulating glucose
uptake and storage into respective peripheral non-exercised tissues62. As a result, the drop
in BG concentrations are potentiated further in the post-exercise period as muscle
glycogen stores are replenished leading to an increased risk of hypoglycemia
development42, 61, 62. Current recommendations for exercise and T1DM include increasing
carbohydrate consumption prior to exercise and the alteration of insulin dosage and
timing, as two key preventative strategies to reduce the risk of exercise-induced
hypoglycemia36. However, there is a tendency for individuals with T1DM to
overcompensate for exercise by consuming excessive amounts of carbohydrates and/or
decreasing insulin doses. This may negate the beneficial effects of exercise by inducing
weight gain from overconsumption and potentially worsen BG control by altering insulin
therapy36. In summary, counterregulatory responses in T1DM are altered due to a
combination of the concentration, timing and actions of exogenous insulin, dysregulated
glucagon response, inadequate hepatic glucose production, excessive pre-exercise
carbohydrate consumption, and post-exercise glycogen recovery36, 42, 62, 63.
Not only are counterregulatory responses to exercise disrupted in T1DM, but there
also appears to be a sex-related difference in individuals with and without T1DM64–68. At
moderate intensities, the neuroendocrine response to exercise appears to be greater in
men65. During euglycemia and hypoglycemia, men with and without T1DM demonstrate
an elevated concentration of epinephrine and glucagon during and following exercise in
comparison to exercised women65, 66. Women with and without T1DM have lower release
concentrations of counterregulatory hormones including glucagon, epinephrine,
norepinephrine, and growth hormone, with a concomitant reduction in hepatic glucose
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production following exercise65, 69. Interestingly, despite reduced release concentrations
of these counterregulatory hormones, it has been suggested women have greater
sensitivity to the action of these hormones and thus require lower concentrations to elicit
an equal response65, 70. Moreover, counterregulatory responses appear to be reduced with
subsequent exercise in individuals with and without T1DM and of both sexes67, 68, 71.
To implement exercise regimen strategies repetitive bouts of exercise (i.e., daily)
must be considered. Through exercise or insulin therapy correction, antecedent periods of
hypoglycemic stress results in blunted counterregulatory responses to subsequent
glycemic challenges in both sexes70. However, counterregulatory responses in men are
suppressed twofold when compared to women in response to repeated hypoglycemia70.
Several mechanisms have been proposed to explain these sex-related differences in
counterregulatory responses during repeated bouts of hypoglycemia, and some research
efforts have highlighted differences in substrate metabolism and the important role of
female reproductive hormones in this response66, 70, 72. Specifically, the role of estrogen
(E2) in metabolism has been well documented in studies conducted in animal models,
women with menopause, and performance studies in men supplemented with E273–75. It
has been suggested that women may be less susceptible to the blunted counterregulatory
responses to repeated hypoglycemia through fuel selection differences, particularly with
an increased reliance on lipid metabolism66, 70. Interestingly, the mediated actions of E2
on metabolism have demonstrated enhanced lipolysis and lipid oxidation while reducing
lipogenesis73, 76, 77.
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1.3
The Menstrual and Estrous Cycle and the
Metabolic Impact of Estrogen
With respect to the ovarian cycle, the menstrual cycle can be simplified into two
phases: the follicular phase (FP) and the luteal phase (LP)76, 77. Although there are
individual variations due to genetics, metabolic conditions, age, and race, reproductive
hormones fluctuate in a predictable manner throughout the menstrual cycle78–81. Estrogen
(E2), progesterone, follicle-stimulating hormone (FSH), and luteinizing hormone (LH) all
characteristically rise and fall per menstrual cycle phase76. A typical, or ‘textbook’,
menstrual cycle starting from the first day of menses to the beginning of the next menses
in young, healthy women averages 28 days. The FP, which is more prone to length
variation than the LP, is approximately 12-14 days, where ovulation occurs on the 14th
day76, 82. The LP averages 14 days and is characterized by an increase in E2
concentrations. This increase in E2 suppresses the release of pituitary hormones LH and
FSH, while progesterone is released from the corpus luteum and increases throughout the
LP82. Menses initiates when there is no fertilization and E2 concentrations start to
decrease. To initiate the maturation of new follicles, FSH is released and as the follicle
matures E2 concentrations slowly rise eliciting positive feedback to increase LH
concentrations marking the beginning of the LP76, 77, 82.
E2 is increasingly recognized to be an important regulator of energy homeostasis and
metabolism, particularly in glucose and lipid metabolism73. The metabolic actions of E2
in skeletal muscle, liver, and adipose tissue improves insulin sensitivity and glucose
tolerance and alters substrate metabolism at rest and during exercise in men and women73,
83–85

. Among eumenorrheic women, E2 functions as a circulating steroid hormone that
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acts on target tissues and mediates its effects by binding to three main estrogen receptors
(ER) – E2 receptor α (ERα), E2 receptor β (ERβ), and the most recent discovery, G
protein-coupled E2 receptor 1 (GPER)85. ERs transmit physiological signaling in
response to E2 and have distinct expression patterns in tissues including the liver, adipose
tissue, skeletal muscle, and breast tissue86. Primarily produced in the ovaries, E2, in its
most common form 17β-estradiol, is carried through the bloodstream to target tissues
where it binds and activates ERs acting as a transcription factor to regulate gene
expression of important cellular factors involved in growth, differentiation, and
homeostasis83, 87, 88. ERs act by regulating transcriptional processes through various
signaling mechanisms85. There are two mechanisms in which E2 exerts its actions, the
genomic or nongenomic signaling pathway89. The genomic effects of E2 are mediated by
the nuclear translocation of an E2-ER complex which directly binds to estrogen response
elements on the promoter region of targeted genes88, 90. Alternatively, the E2-ER complex
can bind to transcriptional coactivators to induce gene transcription indirectly91.
Nongenomic E2 signaling results in more rapid effects of the hormone whereby the E2ER complex, or E2 bound to GPER (non-nuclear, membrane-associated ER) activate
signaling molecules such as cyclic-AMP or phosphoinositide 3-kinase92–94. Protein kinase
cascades alter the function of proteins in the cytoplasm leading to no gene regulation but
instead indirectly influences gene expression through transcription factors87.
Due to the ability to assess novel therapies and investigate a large range of molecular
mechanisms, research on the effects of E2 has predominantly been conducted in animal
models particularly in rodents95–97. The estrous cycle in rodents is equivalent to the
menstrual cycle in humans and is comprised of four phases (proestrus, estrus, metestrus,
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and diestrus), repeating every 4 to 5 days. Metestrus and diestrus typically have the
highest concentrations of progesterone while proestrus is recognized for higher
concentrations of E2 which remain elevated for 12 hours95, 96.
Rodent models are especially helpful to delineate the pathogenesis of metabolic
disorders and many diabetes mellitus rodent models present sexual dimorphism in
glucose regulation and associated complications97, 98. For example, as similarly observed
in human patients, chronic hyperglycemia is pronounced in males while females remain
more normoglycemic98. To thoroughly investigate the role of reproductive hormones and
particularly the metabolic impact of E2, ovariectomized (OVX) rodents are commonly
used. OVX models have consistently shown altered glucose homeostasis by impaired
glycemia and insulin secretion and reduced glucose tolerance99, 100. Additionally, other
models such as ERα or aromatase knockout mice, resulting in ablated receptor signaling
and depleted estrogen synthesis, are characterized by reduced lipid oxidation,
hyperinsulinemia, and increased adiposity and hepatic glucose output101. Menopausal and
postmenopausal women, characterized by the gradual systemic loss of E2, demonstrate
similar metabolic phenotypes including increased adiposity, decreased insulin sensitivity,
and the development of insulin resistance102, 103. Moreover, E2 supplementation studies in
rodent and human models with E2 deficiency, such as OVX rats and women with
menopause, have demonstrated favourable outcomes in whole-body metabolic profile
including improved systemic insulin sensitivity, reduced adiposity, and improved glucose
tolerance74, 104, 105.
A clear sexual dimorphism is present in neuroendocrine and metabolic responses to
exercise. As aforementioned, women are less susceptible to the blunted counterregulatory

14

responses to repeated hypoglycemia, and this may be explained by differences in
hormone concentrations and fuel selection. At rest, there are no apparent differences in
fuel selection between men and women, however throughout various types of exercise it
is well established women with and without T1DM rely more on lipid metabolism,
demonstrated by lower respiratory exchange rate (RER), whereas men favour
carbohydrate oxidation for fueling exercising muscles66, 70, 106. Additionally, female
skeletal muscle has consistently shown more capacity for lipid transport, intramyocellular
triacylglycerol (IMTG) production, and β-oxidation103. This is supported through higher
expressions of genes associated with fatty acid transport and synthesis (i.e., FAT/CD36,
lipoprotein lipase, carnitine palmitoyl transferase I (CPT I))107. This predominant use of
lipids as fuel source is also related to E2-induced inhibition of gluconeogenic-mediated
hepatic glucose output and lower depletion of hepatic and muscle glycogen105. Moreover,
E2 supplementation in exercising men has resulted in a shift towards lipid utilization
through significantly lower RER 66, 74. OVX rats demonstrate an increase in muscle and
hepatic glycogen use during a 4-week exercise regimen and E2 supplementation reversed
this effect by attenuating glycogen use and increasing lipid oxidation75. Another study in
OVX rats demonstrated similar results whereby there was an increased availability of
lipids for oxidation and spared glycogen with E2 administration over a 2-week period 106.
Fluctuating hormones concentrations during the menstrual cycle are believed to
influence the metabolic responses to exercise depending on the phase of the menstrual
cycle they are tested in108. Typically, women are tested during the FP because hormone
concentrations, particularly E2, are relatively stable and similarly observed to
concentrations in men66. However, these methodologies limit the influence of E2 on
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study outcomes. Studies examining exercising women during the LP have shown there is
a higher concentration of circulating E2 elucidating a higher relative rate of fatty acid
oxidation (FAO) in comparison to the FP107–109. Furthermore, phase specific differences
are evidenced through increased preservation of total and muscle glycogen in women
exercising in LP, while women exercising in FP and men have similar glycogen use107.
The literature supports the increasing availability of lipids for substrate oxidation and
glycogen sparing during exercise, particularly in LP, which can be attributed to the
influence of E2.

1.4
Exercise-Associated Fuel Metabolism in Acute and
Repetitive Exercise in Non-Diabetics
Exercise-associated fuel metabolism involves an integrated system between various
tissues, however the main tissues for energy provision and utilization are the liver,
skeletal muscle, and adipose tissue110–113. Increasing energy demands from exercise
necessitate an increase in energy marked by increased glucose uptake in the muscle and
increased utilization of lipids and glycogen110, 114. The proportion of fuel source provided
by the liver, adipose tissue, and the muscle itself is a delicate balance and depends on
many factors. For the purpose of this overview, the contribution and processes of
respective tissues will be explained in the context of moderate-intensity exercise as
evidence supports a modest amount of moderate-intensity is adequate for significant
health benefits115.
Once exercise commences glucose utilization immediately rises in the muscle with
the breakdown of glycogen stores (glycogenolysis)113, 116. Rapid uptake of glucose from
the blood also increases via a 20-fold increase in blood flow to the exercising muscle113,
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117

. During exercise, increased glucose production from the liver continues to play a

major role in maintaining plasma BG concentrations114, 118. The main substrates and the
proportion of each substrate utilized during exercise largely depends on the intensity and
duration of the exercise performed110, 113, 119. Carbohydrates in the form of muscle
glycogen and plasma BG, and lipids from plasma FFAs and IMTGs are the primary fuel
sources for exercising muscles116. Lower intensity exercise (~25% VO2max) relies more
on lipids for energy and as exercise intensity increases (~65% VO2max) plasma FFAs
decrease while IMTG oxidation increases110, 113, 119, 120. However, lipids cannot be
sufficiently oxidized to match the rate of energy utilization, therefore the other half of
energy is derived from carbohydrate oxidation mainly from muscle glycogen112. Heavyintensity exercise (~85%VO2max) is primarily fueled by muscle glycogen and although
the rate of lipid oxidation decreases, IMTGs directly release FFAs into the cytosol of the
muscle avoiding the muscle plasma membrane for quick use110, 112. Fuel utilization
becomes more complex with the inclusion of a pre-exercise meal. A rich carbohydrate
meal prior exercise, a common practice among individuals with T1DM to attenuate the
risk of hypoglycemia, blunts FFA mobilization, increases muscle glycogen, and typically
enhances exercise performance121.
Skeletal muscle metabolism is in part dictated by individual fibre type that comprise
each muscle and this composition can change with diet, exercise, and disease
conditions122, 123. Muscle fibre type can be divided into two categories, type 1 and type 2
fibres and this distinction is based on the different myosin heavy chain isoforms.
However, muscle fibres were initially distinguished as white and red muscle based on the
different amounts of myoglobin present122. Now characterized as slow twitch or type 1
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and fast-twitch type 2a, red muscle fibres are mitochondrial-rich and are more resistant to
fatigue and better suited to continuous aerobic movement. Alternatively, white muscle
fibres or fast glycolytic 2x fibres (predominant in humans) and 2b fibres (predominant in
rodents) have less mitochondria thus produce ATP via glycolysis and are more suited to
fast movements. During continuous, moderate-intensity exercise type 1 fibres are
predominantly recruited and have a great capacity to oxidize lipids for fuel122, 123.
At the onset of exercise, contraction-mediated cellular events facilitate the
translocation of GLUT4 to the sarcolemma in skeletal muscle for glucose uptake from
circulation124. Skeletal muscle lipid metabolism increases with the use of lipids in the
form of FFAs and triglycerides (TG). To facilitate the availability of lipid sources, an
increase in blood flow and transport into the muscle are required113. Additionally, a
reduction in insulin concentrations is required to release its inhibitory effect on the
activity of proteins responsible for the expression of genes involved in lipid
availability116, 122. Derived from adipose tissue, FFAs are transported through fatty acid
translocase (FAT/CD36) into muscle, allowing the uptake of long-chain fatty acids
(LCFA). Alternatively, derived from circulation or wrapped in very-low-densitylipoproteins from the liver, TGs are hydrolyzed by lipoprotein lipase and are increasingly
used as exercise intensity increases119, 124. FAT/CD36 is more predominant in type 1
fibres and its expression at the membrane is increased in response to exercise training125,
126

. Once transported into the muscle, FFAs are either directed to the mitochondria for

oxidation or stored as IMTGs112. The rate-limiting enzyme CPT1 is essential for
mitochondrial oxidation and converts LCFA-CoA into acyl carnitine to cross the inner
membrane127. Malonyl CoA is a known inhibitor of CPT1 and is produced by the enzyme
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acetyl-CoA carboxylase (ACC) and degraded by malonyl CoA decarboxylase (MCD)127.
5' adenosine monophosphate-activated protein kinase (AMPK) inactivates ACC and
contraction can activate MCD. Therefore, any mechanism which increases AMPK
activity releases the inhibition on CPT1 promoting lipid oxidation in muscle128. Exercise
alters intracellular AMP:ATP ratio and reduces intramuscular glycogen concentrations,
both known activators of AMPK, therefore during exercise lipid oxidation should
increase by way of increased AMPK activity129, 130. It has been well documented many of
the changes in lipid-based metabolism during exercise are directly mediated by
AMPK130.
While the muscle uptakes and oxidizes energy between carbohydrates and fats, the
liver matches the utilization with increased mobilization of hepatic glycogen and GNG to
maintain blood glucose homeostasis114, 131. In T1DM, GNG is the predominant pathway
for hepatic glucose production during exercise132. At moderate-intensity exercise,
determined primarily by glucagon action, GNG is a process that transforms noncarbohydrate substrates into glucose including lactate, amino acids, and glycerol131. For
instance, pyruvate derived from lactate and alanine enters the mitochondria to be
carboxylated into oxaloacetate (OAA). OAA is then reduced to malate to enter the
cytoplasm where its reoxidized into its original form and then transformed into
phosphoenolpyruvate (PEP) by a rate-limiting enzyme PEP carboxykinase (PEPCK).
PEP then enters the gluconeogenic cycle to ultimately be converted into glucose-6phosphate (G6P). Finally, G6P is converted into glucose via another rate-limiting enzyme
glucose-6-phosphatase (G6Pase)118, 131, 132. Other precursors such as glycerol are
converted into glyceraldehyde-3-phosphate and enter the gluconeogenic cycle while
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amino acids are converted into specific intermediates in the tricarboxylic acid cycle
before entering the gluconeogenic cycle131, 133. Although GNG is simplified as the
reversal of glycolysis (the breakdown of glucose into energy) there are four unique
gluconeogenic enzymes essential for overcoming irreversible glycolysis reactions132. In
particular, PEPCK and G6Pase are significantly important to GNG and their deficiency
contribute to liver dysfunction and glycogen storage disease, along with hypoglycemia
and hyperlipidemia132. Increased FFA availability and oxidation has been associated with
an increase in GNG while the inhibition of lipolysis has shown to dramatically decrease
this pathway134. Interestingly, males demonstrate higher basal content of both PEPCK
and G6Pase while females may present reduced rates of GNG due to the influence of sex
steroid hormones such as estrogen135–137. Studies have demonstrated that E2 reduces the
expression of PEPCK and G6Pase thereby downregulating GNG137, 138.

1.5
Exercise-Associated Fuel Metabolism in Acute and
Repetitive Exercise in T1DM
Similar to individuals without T1DM, the fuel source for exercising muscles in
T1DM depends on the duration and intensity of exercise42. However, abnormalities in
fuel metabolism during exercise in T1DM have been recognized and appear to depend on
the state of BG determined by exogenous insulin concentrations42, 62, 122. As previously
described in section 1.2, alterations in neuroendocrine and hormonal responses to
exercise in individuals with T1DM are primarily attributed to deficient endogenous
insulin and/or excessive exogenous insulin. Hepatic glucose production may be inhibited
due to the likelihood of elevated concentrations of insulin at the onset of exercise due to
exogenous insulin therapy and increased insulin sensitivity62. In individuals with T1DM
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that are deprived of insulin for 12-24 hours, prolonged moderate-intensity exercise is
associated with lower RER and consequently a reduced rate of carbohydrate oxidation in
comparison to non-T1DM at the same exercise intensity139. It is postulated that
individuals with T1DM rely more on lipid oxidation during exercise when insulin
concentrations are low than when they have elevated insulin concentrations, mirroring
normal physiological conditions139, 140. Alternatively, in hyperinsulinaemic conditions
substrate metabolism in individuals with T1DM is marked by low lipid oxidation and
increased muscle glycogen utilization presenting risk for early fatigue140. A comparison
of individuals with T1DM exercising in euglycemia versus hyperglycemia concluded the
latter condition relies heavily on carbohydrates while the former reveals a shift towards
lipid oxidation140. This suggests that substrate oxidation in individuals with T1DM
performing aerobic exercise in euglycemia is comparable to that observed in non-T1DM,
demonstrating a shift towards lipid oxidation throughout the course of exercise.
Therefore, when the concentrations of insulin are moderately controlled and circulating
concentrations are near physiological concentrations, the ratio of carbohydrate to lipid
utilization during exercise in T1DM is similar to that of individuals without diabetes62.
However, achieving tight glycemic control is challenging for individuals with T1DM as
30 to 50% of diabetes patients do not meet glycemic control targets141. Typically, in nondiabetic subjects, insulin concentrations decline considerably to 30 pmol/L or less during
exercise, whereas the average pre-prandial insulin concentration in individuals using a
basal bolus insulin regimen is typically 120-180 pmol/L142, 143. Therefore, depending on
the exercise timing and peak action of therapeutic insulin, individuals with T1DM will
likely be carrying out exercise in hyperinsulinaemic conditions.
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Although acute exercise studies are beneficial to understand specific processes and
mechanisms, repeated exercise or exercise training studies are more applicable to
prescribing an exercise regimen. Exercise training is well known to elicit adaptations in
fuel metabolism144–146. A trained state adaptation has consistently shown increased
reliance on lipid oxidation during submaximal exercise while sparing carbohydrate
sources (e.g., muscle glycogen)147. This dependence on lipid oxidation is reflected by
lower RER and is interestingly associated with lower plasma FFA concentrations
suggesting trained muscles may utilize plasma FFAs more rapidly than untrained
muscles148. Regular exercise has also shown to increase GLUT 4 tissue concentration in
muscle leading to improved glucose disposal and glycogen storage149. Although some
studies have investigated exercise-associated fuel metabolism in T1DM and strategies for
T1DM athletes have been developed, it has not been thoroughly investigated if exercise
training elicits similar adaptations in fuel metabolism in T1DM as seen in nondiabetic
individuals150, 151. However, as aforementioned in section 1.2, in response to subsequent
exercise, the counterregulatory responses to hypoglycemia may be preserved in females
with and without T1DM in comparison to males. During exercise, when BG
concentrations are reduced below 3.8 mmol/L counterregulatory responses are observed
and hormones such as growth hormone and cortisol are secreted to increase lipolysis and
FFA mobilization42, 152.
Neuroendocrine and hormonal responses are significant coordinators of fuel
utilization. Evidence suggests that males demonstrate suppressed counterregulatory
responses to repeated hypoglycemia in comparison to females with and without T1DM
and this may be due to fuel partitioning differences in response to exercise65. The
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physiological mechanisms underlying these differences are inconclusive, but evidence
supports the reproductive hormone E2 has a contributory role particularly in lipolytic
metabolism70, 105. Interestingly, evidence has shown E2 can activate AMPK in skeletal
muscle potentially explaining its lipolytic metabolic actions and supporting the
plausibility that women may be protected against acute or repeated exercise-induced
hypoglycemia through a stronger reliance on lipid metabolism in comparison to men153.

1.6
Enhanced Lipid Oxidation Through EstrogenMediated Activation of AMPK
E2 is associated with a shift in fuel usage towards increased lipid oxidation while
reducing carbohydrate metabolism and sparing glycogen stores74, 75, 104, 154. As a result,
this increased flexibility in substrate utilization may be a mechanism which females with
T1DM favour to preserve the counterregulatory response following prior hypoglycemia.
A recent study from our laboratory demonstrated that females with T1DM had greater
post-exercise BG recovery in response to repetitive exercise-induced hypoglycemia in
comparison to males155. This study was staged such that the last day of exercise coincided
with the proestrus phase of the estrous cycle (high E2). It can therefore be suggested
T1DM females were able to recover and stabilize BG post-exercise quicker than males as
a result of E2-mediated actions on fuel selection.
E2-induced activation of AMPK, particularly its α-catalytic subunit, has been noted in
various tissues including skeletal muscle, adipocytes, hepatocytes, endothelial cells,
cancer cell lines, and myotubes153, 156–160. An important mediator of the beneficial
metabolic effects of exercise, the mechanisms of AMPK activation have been well
investigated with various findings161–166 A particular study assessed the potential role of
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AMPK activation in mediating the metabolic effects of E2, mainly in lipid metabolism153.
AMPK phosphorylation (Thr-172) was assessed in muscle, liver, and adipose tissue of
OVX mice in a control or E2 supplemented condition. A significant increase (~5-fold) in
AMPK phosphorylation was evident in skeletal muscle of OVX mice treated with E2.
This suggests that E2 administration, to re-establish and maintain circulating
physiological concentrations of E2, selectively up-regulates AMPK activity in skeletal
muscle of OVX mice. This study also demonstrated that within minutes E2 rapidly
activated AMPK in myocytes, suggesting E2 can directly activate AMPK in a nongenomic manner. Importantly, this rapid increase in AMPK phosphorylation was
inhibited by a selective antagonist on ERs, thus demonstrating E2 can stimulate rapid and
robust AMPK phosphorylation through non-genomic activation of membrane-bound
ERs. Conversely, one study demonstrated that despite higher lipid oxidation and similar
basal AMPK expression, protein content, and activity, women had lower AMPK
activation than men (~200% increase )167. However, this study was conducted during the
mid-follicular phase when E2 concentrations are low. These findings suggest the
mediation of E2 on the beneficial metabolic effects of AMPK may be favourable for lipid
metabolism during exercise. In periods of low E2 such as the FP, the slower classical,
genomic actions of E2 may allow benefits of an upregulated lipid metabolic pathway and
explain consistently observed sex differences in exercise studies which are conducted in
the FP168. However, in periods of increased E2 concentrations such as the LP, additional
non-genomic actions of E2 can maximize the benefits of lipid metabolism153.
As aforementioned, a recent study in our laboratory demonstrated that in response to
repetitive bouts of exercise during proestrus T1DM female rats demonstrated a greater
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BG recovery post-exercise than T1DM males155. Both T1DM males and females rats
repeatedly demonstrated drops in BG throughout the 4-day protocol compared to nonT1DM rats. T1DM rats also demonstrated depleted liver glycogen content; however,
T1DM females were able to stabilize BG more effectively post-exercise than T1DM male
rats. Therefore, it appears females with T1DM may have a protective mechanism against
exercise-induced hypoglycemia that males do not. The mechanism which underlies this
proposed acute E2-mediated protective effect in T1DM is unknown, however it is
plausible non-genomic activation of AMPK via E2 results in an associated enhancement
in lipid oxidation.

1.7

Rationale

Antecedent periods of hypoglycemic stress induced by exercise results in less
effective and/or blunted counterregulatory responses to subsequent glycemic challenges67,
70

. This blunted effect of counterregulatory responses to subsequent hypoglycemia

appears to be sexually dimorphic whereby women are better able to preserve the
counterregulatory defense than men65, 69, 70, 72. Our laboratory recently demonstrated that
T1DM females appear to be more protected against hypoglycemia development during
repetitive exercise155. This may be due to fuel selection differences between the sexes
whereby women have an increased reliance on lipid metabolism during exercise thus
allowing for quicker normalization of BG concentrations by conserving muscle glycogen
and plasma glucose. It appears E2 plays a major role in these differences with consistent
evidence demonstrating E2 enhances lipid availability and oxidation73, 168. Several studies
have demonstrated increased lipid metabolism and reduced glycogen usage during
exercise throughout the menstrual cycle, in particular during the LP when E2
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concentrations are high107, 108. Altogether, in response to repetitive bouts of exerciseinduced hypoglycemia, females may demonstrate a fuel selection shift towards lipid
oxidation while conserving carbohydrate energy stores resulting in more efficient BG
recovery. This proposed fuel selection-associated protective effect may be more
pronounced during exercise in the LP.
The underlying mechanisms which explain why hypoglycemia risk may be lower in
T1DM females in response to repetitive exercise during proestrus remain to be
determined. The mechanistics of E2’s metabolic action on lipid and glucose metabolism
are not clear but there is evidence to suggest that nongenomic activation of AMPK may
mediate its actions153. Activation of AMPK increases lipid oxidation which in turn may
alleviate glycemic challenge by reducing glucose provision demand and conserving
muscle glycogen stores for quicker BG recovery. An E2-mediated shift towards lipid
oxidation also suggests glucose producing metabolic pathways would decrease, such as
GNG which is regulated by the transcriptional modulation of key rate-limiting enzymes
PEPCK and G6Pase134, 137. E2 has shown to decrease the expression of PEPCK and
G6Pase thereby decreasing GNG. A decrease in GNG may further promote a fuel
selection shift towards lipids; however, it is unclear how this may influence T1DM as
GNG is the predominant for glucose provision during exercise.
Understanding sex-related differences present in fuel metabolism during different
metabolic states and conditions (i.e., menstrual cycle phase, T1DM) could contribute to
the development of sex-specific preventive and therapeutic strategies including exercise
programs. For individuals with T1DM, recommendations modified for each sex has the
potential to assist in achieving and sustaining euglycemia during and following exercise.
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1.8

Purpose and Hypotheses

The purpose of this study was to investigate the underlying mechanisms which
mitigate the hypoglycemic risk in response to repetitive bouts of aerobic exercise during
proestrus in streptozotocin-induced T1DM female rodents compared to males. We
examined whether repetitive bouts of exercise-induced hypoglycemia would result in sexrelated differences in fuel selection and whether exercise in proestrus maximized the
benefits of E2-mediated action on glucose and lipid metabolism. In particular, we
examined whether a fuel usage shift towards lipids was present and if muscle glycogen
stores were conserved in T1DM females. We also examined AMPK activity and whether
there was an enhanced E2-induced activation of AMPK in exercising females. Moreover,
we examined whether AMPK activity corresponded to alterations in lipid metabolism
through β-oxidation activity measures. Lastly, we examined if key GNG enzymes
expression would change in response to an E2-mediated shift in lipid oxidation.
We hypothesized that females with T1DM would have a greater preference towards
lipid oxidation during exercise in proestrus than males. Secondly, we hypothesized that
AMPK activity would be greater in females as a result of E2-induced activation and
would correspond to higher lipid oxidation. Lastly, we hypothesized higher lipid
oxidation would correspond to decreased GNG (i.e., PEPCK and G6Pase expression) and
this would elicit a conservation of carbohydrate energy stores (i.e., muscle glycogen) in
females.
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Chapter 2
2.1 Introduction
Insulin producing β-cells of the pancreas are destructed in an autoimmune
reaction in Type I diabetes mellitus (T1DM)1, 2. This metabolic disorder results in
insufficient endogenous insulin leading to elevated concentrations of blood glucose
(hyperglycemia)2. In the absence of insulin therapy, T1DM can be fatal and is associated
life-threatening complications such as nephropathy, retinopathy, and cardiovascular
disease3. With the advancement of insulin therapy and increasing regimens available, in
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the 1990s the Diabetes Control and Complications Trial compared intensive insulin
therapy to conventional therapy4. They demonstrated that intensive insulin therapy
reduces the associated complications of T1DM more effectively than conventional
therapy. However, intensive insulin therapy was also associated with a three-fold increase
in hypoglycemia onset in patients5. The fear of exercise-induced hypoglycemia is cited as
one of the most prominent barriers for participating in regular physical activity in
T1DM6. Exercise has demonstrated to provide many benefits for the management of
T1DM including reduced risk for nephropathy and retinopathy, improved cardiovascular
fitness and overall well-being7. Therefore, developing safe exercise recommendations for
T1DM remains a priority.
At rest and during exercise, tight regulatory mechanisms work to maintain stable
BG concentrations to prevent hypoglycemia onset. In individuals with and without
T1DM, antecedent bouts of hypoglycemia have been demonstrated to blunt these
regulatory responses to subsequent bouts of glycemic challenges8. In other words,
repetitive bouts of exercise-induced hypoglycemia increase the risk of subsequent
hypoglycemia through reduced sensitivity to counterregulatory responses (i.e.,
neuroendocrine, hormonal). Interestingly, the blunted effects of counterregulatory
responses to subsequent exercise of moderate intensity are pronounced two-fold in
males9. The impact of sex-related differences in counterregulatory responses to
successive bouts of exercise on hypoglycemic risk is not well understood in T1DM. A
recent study in our lab demonstrated in response to repetitive bouts of aerobic exercise
during proestrus T1DM females had a greater post-exercise BG recovery compared to
T1DM males despite significant drops in BG throughout the exercise sessions (Appendix
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A)10. This finding suggests that while there was an equal drop in BG between T1DM
females and males, females were able to counteract this drop more successfully than
males and may be less susceptible to the blunted counterregulatory responses to repeated
exercise-induced hypoglycemia. T1DM females may have different mechanisms to
normalize BG concentrations resulting in less risk for hypoglycemia development and
quicker BG recovery following exercise.
The role of E2 in fuel metabolism has been well documented and higher E2
concentrations are associated with a shift towards lipid oxidation during exercise11–13. In
eumenorrheic women, circulating E2 concentrations are highest during the luteal phase
(LP), and it has been shown that exercise during this phase results in higher lipid
oxidation than during the follicular phase (FP)14. Additionally, total and muscle glycogen
stores are more preserved after exercise during the LP compared to males as well as
females exercising during FP14. However, the mechanisms which mediate the action of
E2 on fuel selection are not well understood.
A major metabolic enzyme, adenosine monophosphate-activated protein kinase
(AMPK), has shown to be non-genomically activated by E215. The activation of AMPK
is also induced by exercise resulting in the activation of catabolic processes such as lipid
oxidation and inhibition of anabolic processes such as glycolysis16. Although recently
debated, AMPK has shown to increase lipid availability and oxidation during exercise
facilitating a shift towards fats for fuel16–18. A shift towards lipid oxidation would suggest
a reduced need for glucose provision thus relieving glycemic challenge. For individuals
with T1DM, gluconeogenesis (GNG) is the predominant pathway for glucose provision
during exercise and it is regulated by the transcriptional modulation of key rate-limiting
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enzymes, PEPCK and G6Pase19. Reduced expression of these enzymes would suggest
GNG is decreased. Interestingly, E2 has also shown to decrease GNG through reduced
expression of PEPCK and G6Pase20. Although this may indicate a shift towards lipid
utilization, it is unclear how E2-mediated actions on GNG may influence exerciseassociated fuel metabolism in T1DM females. Therefore, whether periods of increased
E2 concentrations provide maximized benefits in lipid metabolism and conserve muscle
glycogen stores with a concomitant increase in AMPK during exercise in T1DM is not
known. Additionally, it is not understood how exercise during proestrus (high E2)
influences the GNG pathway in T1DM. It is plausible exercise during proestrus may
protect T1DM females against exercise-induced hypoglycemia due to an E2-mediated
shift towards lipid oxidation thereby conserving carbohydrate energy stores (i.e., muscle
glycogen) for a quicker BG recovery.
The purpose of this study was to examine the sex-related differences in fuel
metabolism to repetitive bouts of aerobic exercise during proestrus in streptozotocininduced T1DM rats. In particular, we examined whether exercise in proestrus maximized
the beneficial metabolic actions of E2 on lipid metabolism. Moreover, to examine E2mediated action on lipid metabolism AMPK and β-oxidation activity were assessed, as
well as to whether a shift towards lipid oxidation would lead to a change in the
expression of key enzymes in GNG. We hypothesized a sex-related difference in fuel
metabolism would be present such that T1DM females would demonstrate a greater
preference towards lipid oxidation during exercise in proestrus than males. In addition,
we hypothesized that E2-induced activation of AMPK would correspond to greater lipid
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oxidation in females in conjunction with decreased GNG and conserved carbohydrate
energy stores (i.e., muscle glycogen).

2.2 Methods and Materials
2.2.1. Experimental Design
This study is a secondary analysis of data from a previous study from our
laboratory. The study was originally designed to assess the sexual dimorphism in the
blood glucose response to recurrent bouts of prolonged aerobic exercise in T1DM and
control rats. Twenty Sprague Dawley rats (10 male, 10 female) were randomly assigned
into one of four groups: control (non-T1DM) exercise male (CXM, n = 5), control
exercise female (CXF, n = 5), T1DM exercise male (DXM, n = 5), and T1DM exercise
female (DXF, n = 5). Diabetes was induced using daily low-dose streptozotocin
injections over a one-week period. Insulin pellets were surgically implanted as needed to
maintain a blood glucose range of 9-15 mmol/L a target BG range used by exercising
individuals with T1DM10. The exercise protocol consisted of four consecutive days of
treadmill running (1hour, ~75% VO2 max. or 27m/min per day). Day 4 of exercise was
staged during the proestrus stage of the estrous cycle and rats were sacrificed 5 minutes
post-exercise. Liver and skeletal muscle tissues were harvested and stored at -80 °C.
2.2.2. Western Blotting
Liver (right lobe) and muscle (red portion of the vastus lateralis) samples were
removed from storage at -80C and kept on ice. Muscle and liver tissue were weighed (20
mg) and submerged in lysis buffer (15 mM Tris pH=7.0, 600 mM NaCl and 0.1mM
EDTA) for a 1:10 weight-volume (w/v) ratio of tissue to buffer. The buffer-liver mixture
was kept on ice while being subjected to three, 1-3 second pulses by a basic mechanical
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homogenizer (IKA Laboratories). Homogenized samples were transferred into 1.5 ml
Eppendorf tubes and put on a shaker at 4°C for 2 hours. Afterwards, samples were
centrifuged at 4°C at 12 000 rpm for 20 minutes, followed by extraction of supernatant
(Appendix D). A Bradford protein assay (Bio-Rad) was used to determine protein
concentration (Appendix G). Protein samples were prepared with an equal volume of 2x
Laemmli SDS-PAGE (4% SDS, 20% Glycerol, 10% β-mercaptoethanol, 0.015%
bromophenol blue, 0.125M Tris, pH 6.8) and submerged in a 90°C water bath for 5
minutes. The protein concentration of samples loaded onto the gels was ensured to be
within linear range of the assays when using the specified antibodies. Approximately 1525 ug of protein was loaded into 12% polyacrylamide gels and ran at 140V for 2 hours.
Gels were then transferred on nitrocellulose membranes (Bio-Rad) at 4°C at 70V for 1.5
hours. Following transfer, membranes were washed in TBS-T (Tris Buffer Saline, 0.1%
Tween-20) for 5 minutes, 3 times. Membranes were then blocked with a 5% w/v solution
of TBS-T and skim milk powder for 1 hour before being washed in TBS-T 3 times, 5
minutes each time. Once washed, membranes were incubated for 2 hours at room
temperature with primary antibodies detecting: anti-AMPKα2 (Thr172 phosphorylation)
(#2531; Cell Signaling Technology, Danvers, MA, USA), anti-AMPKα (#2532; Cell
Signaling Technology, Danvers, MA, USA), anti-B-actin (ab8227; Abcam, Cambridge,
UK), anti-PEPCK (ab70358; Abcam, Cambridge, UK), and anti-G-6-pase (ab93857;
Abcam, Cambridge, UK) per manufacturer’s instructions. The following day, primary
antibody was removed, and membranes were washed for 10 minutes in TBS-T, 3 times
before being incubated with a 5% w/v solution of skim milk powder, TBS-T and
secondary antibody (#170-6515 Goat pAB anti-rabbit IgG HRP conjugate; BioRad,
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Hercules, CA, USA) at a 1:20000 dilution for 2 hours at room temperature. After
incubation, membranes were washed in TBS-T for 10 minutes, 3 times. Washed
membranes were then prepared in Bio-Rad chemiluminescence substrate and images
were captured using the BioRad Chemidoc MP System. Western blot images were
quantified using image processing program Image J and statistical analyses were
preformed and interpreted using GraphPad Prism.
2.2.3. Muscle Glycogen Content
2.2.3.1 Muscle Homogenization
Muscle (red portion of the vastus lateralis) samples were removed from storage at
-80C and kept on ice. Approximately 20 mg of tissue was excised from the sample and
placed into a 1.5 mL Eppendorf tube (Appendix F). Samples were submerged in 30%
potassium hydroxide solution saturated with sodium sulfate and placed in a 90C water
bath for 30 minutes. Samples were precipitated in 95% ethanol for 30 minutes in an ice
bath, followed by centrifugation at 3000 rpm for 30 minutes. The supernatant was
discarded, and the glycogen pellet immediately dissolved and vortexed in ddH2O.
2.2.3.2. Glycogen Quantification
Homogenized muscle samples were added to a 96 well uncoated plate. A colour
reaction was developed by rapid addition of 5% phenol and 98% sulfuric acid to the
sample. Samples were placed in a water bath (37C) for approximately 20 minutes.
Samples were analyzed in triplicate and read at 495 nm on a microplate reader and
compared to known glycogen standards (Appendix F).
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2.2.4. Muscle Lysate Assessment of β-oxidation (SCHAD Assay)
2.2.4.1. Muscle Homogenization
Muscle (red portion of the vastus lateralis) samples were removed from storage at
-80C and kept on ice. Approximately 30 mg of tissue was excised from the sample and
placed into a 1.5 mL Eppendorf tube (Appendix E). Samples were submerged in buffer (5
mM potassium dihydrogen orthophosphate (K2HPO4), 1 mM EDTA, 0.1 mM DTT; pH
of 7.4) for a 1:10 weight-volume (w/v) ratio of tissue to buffer. The buffer-muscle tissue
mixture was kept on ice while being subjected to three, 1-3 second pulses by a basic
mechanical homogenizer (IKA Laboratories).
2.2.4.2. β-oxidation activity
Homogenized muscle samples were added to a quartz cuvette with assay buffer
(1M Tris-HCl, pH 7.0, 0.5 M EDTA, pH 8.0, 10% Triton X-100) and 5mM NADH. The
mixture was incubated for 4 minutes at 30C allowing for mitochondrial permeability.
Following an additional 1 minute after incubation the reaction was initiated by adding
5mM acetoacetyl CoA. The sample cuvette was vortexed, and the reaction was read for 2
minutes in 30 second intervals on a NanoDrop2000 C Spectrophotometer (Waltham, MA,
USA) at 340 nm.
2.2.5. Data analysis
Western blot quantification, muscle glycogen content, and β-oxidation activity
were analyzed using a two-way analysis of variance (ANOVA), with sex being the
between variable and condition (control and diabetes) being the within variable using
GraphPad Prism 8 (GraphPad Software, Inc., San Diego, CA, USA). When significance
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was obtained a post-hoc analysis was performed using Tukey’s multiple comparisons
test. The level of significance was set at P = 0.05. Values presented in tables and text are
standard error of the mean (SEM).

2.3 Results
2.3.1. β-oxidation activity
β-oxidation, short-chain β-hydroxyacyl-CoA dehydrogenase (SCHAD) assay was
measured in lysates of rat skeletal muscle (red portion of vastus lateralis) to assess lipid
oxidation activity. There was a main effect of sex (P < 0.05, P = 0.0326). There was no
interaction between sex and diabetes (P > 0.05) (Fig 1). There was no effect of diabetes
(P > 0.05). There was no difference in β-oxidation activity between CXF and CXM (P >
0.05) or between DXF and DXM (P > 0.05). Overall, females demonstrated greater βoxidation activity than males.
2.3.2. AMPK expression and activity
Western blot analysis of AMPKα was assessed in lysates of rat skeletal muscle
(red portion of vastus lateralis) and demonstrated a main effect of sex (P < 0.05; P =
0.0242) and diabetes (P < 0.05; P = 0.0244). There was no interaction between sex and
diabetes (P > 0.05). There was no difference in AMPKα between CXF and CXM (P >
0.05) or between DXF and DXM (P > 0.05). AMPKα was significantly lower in DXF
compared to CXM (P < 0.05; P = 0.0145). Overall, males demonstrated greater AMPKα
expression than females.
Western blot analysis of phosphorylated AMPKα 2 (p-AMPK), a hallmark of
AMPK activation in muscle, was assessed in lysates of rat skeletal muscle (red portion of
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vastus lateralis) and demonstrated no effect of sex or diabetes (P > 0.05). There was no
interaction between sex and diabetes (P > 0.05). The ratio of p-AMPKα2 to AMPKα
demonstrated no effect of sex or diabetes (P > 0.05) suggesting that the activity of
AMPKα2 was not different between groups.
2.3.3. Muscle glycogen content
Muscle glycogen content was assessed in lysates of rat skeletal muscle (red
portion of vastus lateralis) and demonstrated no effect of sex or diabetes (P > 0.05). There
was no interaction between sex and diabetes (P > 0.05). There was no difference in
muscle glycogen between CXF and CXM (P > 0.05) or between DXF and DXM (P >
0.05).
2.3.4. Gluconeogenic enzymes
Western blot analysis of G6Pase and PEPCK, rate-limiting enzymes in the
gluconeogenesis pathway, were assessed in lysates of rat liver tissue. G6Pase
demonstrated a main effect of sex (P < 0.05; P = 0.0080). There was no effect of diabetes
(P > 0.05). There was no interaction between sex and diabetes (P > 0.05). G6Pase was
lower in both CXM and DXM compared to CXF (P < 0.05; P = 0.0173; P = 0.0262).
There was no effect of sex or diabetes in PEPCK content (P > 0.05). There was no
interaction between sex and diabetes in PEPCK content (P > 0.05). Overall, females
demonstrated greater G6Pase expression than males.
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2.3.5 Blood glucose concentrations
Refer to Appendix A. Previous findings from our laboratory conclude on day 4 of
exercise DXF demonstrated a quicker post-exercise BG recovery compared to DXM
despite similar drops in BG throughout the exercise session.
2.3.6. Estrogen concentrations
Refer to Appendix B. Previous findings from our laboratory verified circulating
E2 serum concentrations by comparing day 1 to day 4 concentrations to confirm the
proestrus phase on day 4.

Figure 1. β-oxidation, SCHAD activity assessment of skeletal muscle in male and female
T1DM and control rats. Mean muscle SCHAD activity (μmol·g wet wt−1·min−1) from day
4. All data are presented as mean  SEM. There was a main effect of sex. DXF and CXF
demonstrated greater β-oxidation activity than DXM and CXM. *Denotes significance.
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Figure 2. Western blot quantification and representation blots
of AMPKα and p- AMPKα2 from day 4 of exercise protocol for
control and diabetic exercise males and females. (a) AMPKα
(b) p- AMPKα2 (c) Phosphorylated ratio and (d) Representative
blots relative to β-actin control. All data are presented as mean
 SEM. * denotes significance. There was a main effect of sex
(P = 0.0242) and diabetes (P = 0.0244) for AMPKα. There was
a difference between DXF and CXM in AMPKa (P = 0.0145).
There was no difference in AMPKa between CXF and CXM (P
> 0.05) or between DXF and DXM (P > 0.05). There were no
significant differences in p- AMPKα2.
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Figure 3. Muscle glycogen content measured in umol/g from day 4 of exercise for control
and diabetic exercise males and females. All data are presented as mean  SEM. There
was no significant difference between CXF and CXM or between DXF and DXM (P >
0.05).
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Figure 4. Western blot quantification and representative blots
for gluconeogenic enzymes G6Pase and PEPCK. (a) G6Pase
protein content quantification (b) PEPCK protein content
quantification and (c) Representative blots relative to β -actin
control. All data are presented as mean  SEM. * denotes
significance (P < 0.05). There was a main sex effect in G6Pase
(P = 0.0080). DXM (P = 0.0173) and CXM (P = 0.0262) were
significantly lower than CXF. There were no significant
differences in PEPCK.

2.4 Discussion
Extensive reviews and commentaries have been published to recommend safe
exercise practices and strategies for T1DM management21–25. Yet, individuals with
T1DM are still disproportionately inactive and cite the fear of hypoglycemia as a main
barrier to regular physical activity6, 23. Research efforts examining the role for exercise in
the management of T1DM has focused predominantly on male subjects. Most recent
findings in our laboratory demonstrated that T1DM females had a better post-exercise
BG recovery compared to T1DM males in response to repetitive bouts of aerobic exercise
in proestrus (Appendix A)10. While T1DM males and females presented significant drops
in BG throughout the course of exercise, it appears females were able to stabilize BG
concentrations post-exercise more efficiently than T1DM males. This finding suggests
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that T1DM females may be less susceptible to the blunted counterregulatory responses to
subsequent exercise-induced hypoglycemia. Moreover, this finding suggests that T1DM
females may be less susceptible to hypoglycemia development during exercise in
proestrus due to the metabolic actions mediated by E2.
It has been postulated women are better at maintaining BG homeostasis during
exercise due to sex-related differences in the fuel selection9, 11. The role of E2 is
increasingly recognized in many physiological systems including the glucose
counterregulatory responses to exercise. E2 influences fuel metabolism during exercise
and is associated with a shift in fuel usage towards lipid oxidation thereby preserving
carbohydrate energy sources for quicker BG recovery11–13, 26. Therefore, the purpose of
this study was to investigate the underlying mechanisms which explain why T1DM
females recover more efficiently during repetitive acute aerobic exercise in proestrus,
particularly the sex-related differences in fuel metabolism.
The results of the current study demonstrate that there is a sex-related difference
in lipid oxidation during exercise in females. Both T1DM and non-T1DM females
demonstrated significantly higher β-oxidation activity in skeletal muscle immediately
after exercise compared to T1DM and non-T1DM males (Figure 1). This would suggest a
shift in fuel usage towards lipid oxidation in both T1DM and non-T1DM females during
repeated acute moderate-intensity aerobic exercise. We hypothesized that greater lipid
oxidation in females would correspond to increased AMPK activity as a result of E2induced activation; however, we found no differences in AMPK activity (AMPKα2
phosphorylation) between the sexes (Figure 2b and 2d). AMPKα expression
demonstrated a diabetes effect and was higher in males (Figure 2a). These findings agree
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with previous work demonstrating higher rates of lipid oxidation in females during
exercise in the FP is not associated with a concomitant increase in AMPKα2 activity
compared to males27. This may suggest that females have greater control over energy
balance and increased lipid oxidation is not exclusively mediated by AMPKα2 during
exercise, which has also been supported by recent evidence18. Additionally, our findings
suggest AMPKα2 expression and activation are not necessarily correlated with higher E2
concentrations thus the mediated actions of E2 on lipid metabolism during exercise may
be through other signaling pathways. A study demonstrated an increase in AMPK activity
in exercising men compared to women similarly to the findings presented here, an
increase in AMPKα expression in T1DM and non-T1DM males (Figure 2a)27. However,
the increase in AMPK activity was associated with an increase in lipid oxidation which
was not evident in the males in the current study. An increase in AMPKα expression in
T1DM and non-T1DM males may suggest males require increased concentration of
AMPKα expression to elicit the same activation as females.
We hypothesized that T1DM and non-T1DM females would demonstrate a
greater preference towards lipid oxidation during exercise in proestrus and that this E2mediated fuel shift would in turn conserve muscle glycogen stores. We found no
differences between the sexes in muscle glycogen content (Figure 3). In humans without
diabetes, the LP is associated with less muscle glycogen mobilization during aerobic
exercise suggesting less plasma glucose uptake or carbohydrate intake may be required
for post-exercise glycogen replenishment14. As a result of no baseline muscle glycogen
content our findings cannot verify if there was a difference in muscle glycogen
utilization, nor can we confirm if there were phase specific differences in muscle
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glycogen use. The studies which have concluded a menstrual phase effect on sparing
muscle glycogen content were conducted in isolated bouts of exercise, therefore it can be
postulated there was no muscle glycogen differences between the sexes due to the
exhaustive nature of the prescribed exercise protocol. Successive days of exercise have
demonstrated to produce a marked reduction and utilization of muscle glycogen content.
In particular, a study investigated a 3-day running protocol on muscle glycogen content
and utilization28. On day 1, pre-exercise muscle glycogen content was approximately 2.1
g/100g and 1.4g/100g post-exercise. However, on the third consecutive day of running,
muscle glycogen content pre-exercise was reduced to 1.3 g/100g and approximately 0.7
g/100g post-exercise. Muscle glycogen content of our rats on day 4 post-exercise ranged
from approximately 0.25 g/100 g to 0.64 g/100g which is substantially lower than the
muscle glycogen content post-exercise on day 3 in the aforementioned study. These
values suggest that on day 4 the exercised rats in the present study were likely depleted of
muscle glycogen. Indeed, post-exercise muscle glycogen stores can take up to >24 hours
for complete restoration to near pre-exercise concentrations29. Therefore, the successive
exercise protocol likely did not allow for full resynthesis of stores and a sparing effect
regardless of the mediated action of E2 was difficult to achieve.
Our lab has previously demonstrated that liver glycogen content is significantly
depleted in T1DM males and females coinciding with significant drops in BG throughout
exercise compared to the control groups (Appendix C). We hypothesized a decrease in
hepatic GNG in females as a result of higher E2 concentrations. Interestingly, hepatic
gluconeogenic rate limiting enzyme G6Pase was significantly higher in T1DM and nonT1DM females, but no difference between groups was seen in PEPCK content (Figure
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4). This may suggest that hepatic GNG was in part increased in females as a result of
increased precursor availability of glycerol from the breakdown of stored
triacylglycerols. Enhanced E2-induced lipid oxidation in females suggests an increase in
lipid availability from increased lipolysis leading to higher circulating gluconeogenic
precursors free fatty acids and glycerol. The pathway of glycerol into GNG is short and
bypasses the tricarboxylic acid cycle and thus G6Pase content is primarily relevant for its
conversion into glucose30, 31. It can therefore be suggested higher G6Pase expression in
females may reflect increased GNG from glycerol. As tissues were harvested during
proestrus (Appendix B), it appears a E2-mediated shift towards lipid oxidation in T1DM
and non-T1DM females did not correspond to decreased GNG, rather higher precursor
availability may have increased GNG through increased G6Pase expression.
Our findings in PEPCK content may also suggest GNG from other precursors
such as lactate and amino acids is equal between groups during exercise, however we
cannot verify this with our data set. PEPCK content is similar between all groups
suggesting the predominant precursor for GNG during exercise in T1DM males may be
different than T1DM females. This may be supported by a notable sex-difference in
rodent models for gene expression of PEPCK and G6Pase whereby males demonstrate
higher basal content of both enzymes32. The rate of hepatic glucose output during
exercise is predominantly balanced through GNG in T1DM and our findings suggest this
pathway may be more upregulated in T1DM females due to increased lipid oxidation33.
This may be one mechanism which can explain why T1DM females demonstrate a
greater resistance to the blunting effects of the counterregulatory responses to repeated
exercise-induced hypoglycemia during proestrus.
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2.5 Conclusion
Both T1DM and non-T1DM females demonstrated higher lipid oxidation
compared to male counterparts. This shift corresponded to elevated concentrations of E2
as exercise was performed during proestrus. We hypothesized that greater lipid oxidation
would correspond to conserved muscle glycogen content, however we found no
difference between the sexes. This is likely due to depleted glycogen stores in all groups
following successive days of high intensity aerobic exercise. Our findings also
demonstrate that the shift towards lipids as fuel during exercise did not correspond to
higher AMPK activity. Therefore, greater lipid oxidation in females during repetitive
bouts of exercise in proestrus cannot be exclusively explained through an AMPK
mechanism. The influence of elevated E2 during proestrus did not negatively impact
GNG, rather the E2-mediated shift towards lipid oxidation increased the enzyme G6Pase
in T1DM and non-T1DM females. An increase in lipid availability likely increased the
availability of glycerol as a GNG precursor. As a result, increased GNG in T1DM
females may have supported glucose provision leading to more stable BG concentrations
post-exercise.
In conclusion, a sex-related difference in lipid metabolism was evident and T1DM
females demonstrated a shift towards lipid oxidation in response to repetitive aerobic
exercise during proestrus. However, this preference towards lipid oxidation was not
accompanied by greater AMPK activity or conserved muscle glycogen stores. Therefore,
T1DM females may demonstrate greater resistance to the blunting effects of repeated
exercise-induced hypoglycemia due to enhanced use of lipids as fuel for exercising
muscle and increased use of GNG precursors (i.e., glycerol) during exercise in proestrus.
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Future directed efforts to study sexual dimorphism in T1DM and lipid/glucose
metabolism would benefit from measurement of muscle glycogen content at baseline and
post-exercise (>24h). In addition, concentrations of blood catecholamines and hormones
such as GH would be beneficial to measure pre- and post-exercise due to its role in lipid
metabolism and on G6Pase expression. Lastly, future studies should prescribe a less
intensive exercise protocol to allow for sufficient muscle glycogen resynthesis thus
providing opportunity for a potential sparing effect.
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Appendices
Appendix A: Mean blood glucose response from day 4 of exercise protocol.
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Appendix B: Serum estrogen concentrations from day 1 and day 4 of exercise
protocol.
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Appendix C: Liver Glycogen Content. Previous findings from our laboratory conclude
on day 4 of exercise liver glycogen content was significantly depleted in diabetes groups
compared to control groups.
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Appendix D: Western Blotting Protocol. Western blotting method for the
quantification of protein expression and phosphorylation of AMPKa, p-AMPKa2,
G6Pase, and PEPCK.
Tissues tested: Skeletal muscle and liver
Sample preparation:
1. Place homogenized samples on ice.
2. Load the amount of protein in each well previously determined by a protein
loading curve.
3. The volume of homogenate needed is determined from a Bradford protein
quantification assay (See Bradford Assay protocol).
4. Label a new set of Eppendorf tubes with the appropriate sample names.
5. Dilute the volume of sample in sample buffer (1:1 ratio) and vortex.
6. Boil sample and buffer mixture for up to 5 minutes at 90°C.
7. Prior loading samples into gel allow samples to return to room temperature. It
may be necessary to vortex or quickly centrifuge samples before loading.
Preparation of gels:
1. Clean short glass plates with 70% ethanol before use and then prepare gel
cassette.
2. Prepare separating gel according to chart relative to the number of gels and
percent acrylamide to be used (12% separating gel recipe was used for all blots in
this study).

3. After 10 minutes of mixing, pour separating gel using Pasteur pipette while trying
to eliminate bubbles.
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4. Immediately overlay the gel with water saturate isobutanol to ensure a continuous
charge from separating to stacking gel.
5. Wait approximately 45-60 minutes for gel to polymerize and rinse off overlay
solution with ddH2O and dry clean with filter paper when stacking gel (4%) is
ready to pour.
6. Prepare and pour stacking gel (4%) according to the chart below:

7. Place the correct sized comb between the glass plates, ensuring no air bubbles are
trapped in the wells continue to pour stacking gel mixture on the ends of the
comb.
8. Prepare 1L of 1x running buffer per 2 gels and store in the refrigerator.
9. Once the stacking gel has polymerized (30 minutes), gentle remove comb and fill
wells with 1x running buffer.
10. Load correct amount of sample and ladder using micropipette with loading tip.
11. Once loading is complete place gels in running unit.
12. Fill running unit with cold 1x running buffer (chamber inside the cassette and the
outside).
13. Run gels at 70V until through the stacking portion of the gel (~30 minutes) and
then 125-130V until sample dye has reached the front of the glass.
14. During the running period prepare transfer buffer and keep in refrigerator.
Transfer of Gels to Nitrocellulose:
1. Cut filter paper and nitrocellulose to appropriate size (short plate size).
2. Soak filter paper, nitrocellulose, and Brillo pads in cold transfer buffer for 20
minutes.
3. Once running period is complete, assemble the transfer apparatus (“sandwich”) as
shown below, making sure to remove all air bubbles between gel and
nitrocellulose paper (keep sandwich completely submerged in transfer buffer at
all times).
4. Place “sandwich” into transfer holding tank making sure the black, negative side
is facing the black transfer unit. Fill tank with cold transfer buffer and add ice
pack into the unit to keep transfer period cold throughout.
5. Connect to power supple and run at 70V for 1.5 hours.
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Blocking:
1. Prepare 1L 1x TBS per 2 blots.
2. After transfer, gently remove gel and place in small container with 5% blocking
solution (optional, rinse gel once with 1x TTBS for 5 minutes before blocking).
Incubate up to 2 hours on shake at room temperature.
3. After blocking prepare primary antibody (minimum 20ml of solution).
4. Wash blots 1x in TTBS for 5 minutes.
5. Incubate blots in primary antibody solution overnight at 4°C or for two hours at
room temperature.
6. Once finished, the primary antibody solution can be stored in the refrigerator for
use within a week or stored in the freezer for long term storage.
7. Wash blots 3x in TTBS for 10 minutes each.
8. Prepare secondary antibody (confirm HRP, not AP) solution (1:5000-25000).
9. Incubate blots for 1 hour on shaker at room temperature.
10. Wash blots 3x in TTBS for 10 minutes each. Keep in 1x TBS for long-term
storage.
Western Blotting Solutions:
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Appendix E: Phenol-Sulphuric Acid Assay. Glycogen content quantification was
assessed with the phenol-sulphuric acid assay.
Part A: Solutions
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1. 30% KOH (w/v)
a. 30 g of KOH pellets
b. 100 mL of ddH2O
c. Exothermic reaction — combine in an Erlenmeyer flask placed in an ice
bath.
2. 95% Ethanol (v/v)
a. 95 mL of 100% Ethanol
b. 5 mL of ddH2O
3. Glycogen Standards
a. 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, and 0.7 mg/mL
b. Prepare large volumes of standards and store in 15 mL Falcon Tubes
c. Standard curve flattens out after 0.7 mg/mL (see below)1
i. Linear portion spans from 0 to 0.6 or 0.7 mg/mL

Glycogen Standard Curve
3
2.5

A490

2
1.5
1

0.5
0
0

0.1

0.2

0.3

0.4

0.5

0.6

0.7

0.8

{Glycogen} mg/mL

4. 100% Sulfuric Acid (stock)
5. 5% Phenol (v/v)
a. 5 mL of 100% phenol (stock)
b. 95 mL of ddH2O
Part B: Tissue Homogenization and Glycogen Isolation
1. Cut and weigh approximately 20 mg of tissue, place into a 2.0 mL Eppendorf tube
and keep on ice until the next step.
2. For 12 samples, saturated ~10 mL of 30% (w/v) KOH solution with Na2SO4.
3. Boil approximately 0.75 L of water and pour into the metal tray on the hot plate. Set
the hot plate to MAX.
1

With a 5% (w/v) Phenol solution, the standard curve was linear from 0.0 – 1.0 mg/mL glycogen
concentrations with an R2 = 0.97.
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4. Add 500 µL of the Na2SO4-saturated KOH solution to each Eppendorf tube, ensuring
that each sample is completely submerged.
5. Place samples in a boiling water bath for 30 minutes. Halfway through, agitate the
tubes until no pieces of tissue are visible.
6. Place tubes on ice and precipitate glycogen by adding 1 mL of 95% ethanol for 30
minutes.
7. Centrifuge tubes at 3000 rpm for 30 minutes.
8. Discard the supernatant and immediately dissolve the pellet in 1 mL of ddH2O.
Part C: Glycogen Quantification
1. Turn on the hot water bath and set it to ~70 °C.
2. In a flat-bottom polystyrene 96-well microplate, pipette 50 uL aliquots of ddH2O,
glycogen standards and sample glycogen solutions in triplicate.
3. Add 150 µL of sulfuric acid to each well.
4. Quickly add 30 µL of 5% phenol to each well.
a. Works best with a repeater pipette. Use a 5 mL CombiTip set to 150 µL for
the sulfuric acid, and a 0.5 or 1.0 mL CombiTip set to 30 µL for phenol.
5. Cover plate in ParaFilm and place in a static hot water bath for 10 minutes.
6. Dry the microplate with KimWipes and measure absorbance using a microplate
reader at 490 nm (1.0 seconds).
7. Calculate glycogen concentration (units: µmol of glycogen/g of tissue):
µmol of glycogen
A490
=
g of tissue
k × W × MMGlycogen
Where:
A490 = Adjusted Absorbance at 490 nm (Sample Absorbance – Blank Absorbance)
k = slope of the standard curve (units µg-1)
W = mass of tissue sample used
MMGlycogen = molar mass of glycogen (666.5777 g/mol)
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Appendix F: β-oxidation, short-chain β-hydroxyacyl-CoA dehydrogenase (SCHAD)
Assay. Muscle lysate assessment of β-oxidation activity of control and T1DM subjects in
red portion of vastus lateralis tissue.
Part A: Solutions
1. Lysis buffer:
a. Measure: 5 mM potassium dihydrogen orthophosphate (K2HPO4), 1 mM
EDTA, and 0.1 mM DTT.
b. Adjust to a pH of 7.4.
2. SCHAD Buffer (50mM Tris-HCl, 1mM EDTA):
a. Make stock 0.5M EDTA (pH 8.0):
i. Measure 146.12g; add to 400 ml of ddH2O.
ii. Add very concentrated NaOH dropwise until pH 8.0 (colour
reaction: white to translucent).
iii. Bring to 500 ml ddH2O.
b. Make 1M Tris-HCl (pH 7.0):
i. Measure 157.6g; add to 1L ddH20.
ii. Adjust pH to 7.0.
c. Make working buffer (~250 sample runs):
i. 100 mL ddH2O
ii. 10 mL stock Tris-HCl buffer (pH 7.0)
iii. 400ul stock 0.5 EDTA buffer (pH 8.0)
iv. Check solution pH (7.0)
v. Bring solution to 200 mL with ddH2O.
3. 5mM acetoacyl CoA (stored at -20°C).
a. 5 mg vial reconstituted in 1.03 mL ddH2O.
4. 10% Triton X-100.
a. 5 mL Triton X-100 diluted in 45 mL ddH2O (stored at room temperature).
5. 5 mM NADH (stored at 4°C).
a. Reconstitute 3.54mg of sample in 1 mL ddH2O.
b. Make fresh daily and keep on ice.
6. Assay buffer (stored at 30°C, made fresh daily):
a. 1 mL Triton X-100
b. 49 mL SCHAD buffer
Part B: Muscle homogenization
1. Place approximately 30 mg of muscle tissue and place into a 1.5 mL Eppendorf
tube on ice.
2. Submerge sample in lysis buffer for a 1:10 weight-volume ratio.
3. Keep buffer-muscle mixture on ice while subjecting to three, 1-3 second pulses by
a mechanical homogenizer.
Part C: Procedure
1. Turn on spectrophotometer and water bath at least 20 minutes prior start. Assay
carried out at 30°C.
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2. Prepare assay buffer fresh daily and keep in water bath at 30°C.
3. “Zero” prior sampling by placing blank cuvettes with only assay buffer.
4. Prepare quartz cuvette (340 nm wavelength cannot penetrate disposable plastic
cuvettes), pipetting repeatedly slowly:
a. 800 uL assay buffer
b. 10 uL NADH
c. 35 uL sample
5. Mixture should be incubated for 4 minutes at 30°C to allow for mitochondrial
permeability in water bath.
6. Start measurement routine following incubation period. Wait an additional 1
minute following the 4-minute incubation period (a total of 5 minutes pre-assay
incubation).
7. Initiate reaction by adding 10 uL of acetoacetyl CoA.
8. Mix sample cuvette using pipette.
9. Read for 2 minutes, every 30 seconds.
10. Calculate:
a. Determine the specific activity (SA):
i. SA = [∆Abs / volume assayed (mL)] / 6.3*10-3 nmol*min-1
b. Total amount of protein available in the homogenate
i. = [protein] mg/mL * mass of wet wt. of tissue * 0.025
c. Total number of units = SA * total amount of protein
d. Units/wet weight = total # of units / total mass of tissue homogenized.
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Appendix G: Bradford Protein Assay. Analytical procedure used to calculate the
concentration of protein in liver and muscle samples.
Procedure:
1. Dilute 1 part dye reagent with 4 parts ddH2O (Bio Rad 500-0006). One
microplate requires 25 mL reagent.
2. Filter the diluted solution through Whatman 1 filter paper (store solution at room
temperature up to two weeks).
3. Add the indicated amounts of BSA (1 mg/mL) or unknown protein sample, water,
and reagent respectively into a 96-well microplate.
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Protein (ug)

Water (uL)

BSA (uL)

0
1
2
3
4
5
6
unknown

10
9
8
7
6
5
4
9.5

0
1
2
3
4
5
6
-

Unknown
sample (uL)
0.5

Reagent (uL)
200
200
200
200
200
200
200
200

4. Shake and incubate at room temperature for a couple of minutes.
5. Read absorbance at 595 nm.
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